Find out more about the ADCs on the cusp of approval, the ADCs we saw approved, enter the clinic, and be discontinued across 2021, get further insight into the record growth in the number of ADC trials and much more.
Discover key collaborations, investments, approvals in 2021 in the adoptive cell field—furthermore, a look to the future of the cell therapies space.
Download a summary of key developments in 2021; regulatory announcements, discontinuation and first entries into the clinic.
The following slides cover the analysis on the phase of trials, drugs in the clinic, drug discontinuations, and regulatory announcements in 2021.
Find out the most popular targets, the number of ICM clinical trials, and regulatory announcements in 2021.
Don’t miss out on our overview of the clinically active cytokine space. This analysis includes the number of cytokine trials started per year and much more.
DNA Damage Response
In this analysis, you will find key updates, regulatory announcements, and a summary of the current DDR landscape.
Discover mergers and acquisitions, gene therapies that entered the preclinical space in 2021, and much more.
Targeted Protein Degradation
The following slides look at the highlights from 2021, including drugs that entered the clinic, regulatory announcements, and collaborations.
Covering all Antibody Drug Conjugates (ADCs), Small Molecule Drug Conjugates (SMDCs), Protein Drug Conjugates (PDCs), Immunotoxins and more
Covering all engineered and non-engineered immune cell therapies, including CAR-T, TCR, NK, TILs, Gamma-Delta T Cells and more
Covering all Bi- and Multi-Specific Antibodies, Antibody Fragments, Augmented Antibodies and more
Beacon Cancer Vaccine provides the solution you need to master the prophylactic and therapeutic cancer vaccines field.
Covering all Immune Checkpoint Combination Trials and Immune Checkpoint Modulators in development across 27 different checkpoint targets
Covering all cytokines and drugs that target a cytokine or its immediate receptor belonging to the Interleukins, Interferons, Colony-stimulating factors, Transforming growth factor β, Tumour necrosis factor and Chemokines families.
Beacon DDR steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the DDR field.
From gene-editing technologies, novel delivery systems, and a variety of genetic materials being used- Beacon Gene Therapy steps into the field to give drug developers a precise and detailed view of how the gene therapy landscape looks.
Covering Oligonucleotide-based, mRNA-Based, Ribozyme, and gRNA-Mediated Gene Editing therapies, as well as RNA-Targeted Small Molecules – Beacon RNA covers all disease indications and many modalities to provide a detailed landscape of the RNA space.
From capturing viral family and strains to understanding any genetic modifications – Beacon Oncolytic Viruses steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the Oncolytic Virus field.
Beacon TPD provides the solution you need to master the targeted protein degradation field.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements